NewAmsterdam Pharma faces lowered earnings estimates after Investor Day

NewAmsterdam Pharma (NASDAQ: NAMS) recently held its annual Analyst/Investor Day on August 5, 2026. The event featured presentations from executive leadership, including CEO Michael Davidson and Chief Scientific Officer Johannes Jacob Kastelein, covering corporate updates, scientific developments, and commercial progress.

Following the event, HC Wainwright issued a pessimistic outlook for the company, lowering its Q3 2026 earnings per share (EPS) estimate to ($0.62) from a previous estimate of ($0.58). This follows a recent quarterly report where the company reported an EPS of ($0.52), missing the consensus estimate of ($0.48).

Despite these lowered estimates, various analysts maintain different positions on the stock. Jefferies Financial Group holds a "buy" rating with a $45.00 price objective, while BMO Capital Markets issued an "outperform" rating with a $58.00 target. Royal Bank of Canada recently adjusted its target price from $51.00 to $50.00, maintaining an "outperform" rating.